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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: OCT assessment was available in 119 patients. Nine had a MACE (peri-
procedural myocardial infarction, myocardial infarction during follow-up or cardiac
death), while 110 had no complications (control group). The control group showed a
smaller number of cross section with residual thrombus area >10% respect to MACE
group (8.269.49 vs 16.0012.25; P¼ 0.02) and a smaller mean Thrombus area %
(4.712.64 vs 6.332.94, p¼ 0.08).
Conclusions: Residual intrastent thrombus is associated with higher incidence of
cardiac events during follow-up in STEMI patients treated with primary angioplasty
despite the adoption of aggressive strategy for thrombus removal.
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Background: Recent Frequency Domain Optical Coherence Tomography (FD-OCT)
studies showed that, even with the use of aggressive technical solutions, a
complete removal of thrombotic materials is rarely achieved after percutaneous
coronary interventions (PCI) for ST-segment elevation myocardial infarction
(STEMI). Residual intra-stent thrombus can result in distal embolization leading to
microcirculatory injury. The aim of this study was to ﬁnd a possible correlation be-
tween residual intrastent thrombus and angiographic indexes of myocardial
reperfusion.
Methods: COCTAIL II enrolled 128 STEMI patients which underwent primary PCI
within 6 h from onset of chest pain and randomized to one of the following four
treatments: local infusion of abciximab delivered by the ClearWay with (group 1) or
without thrombectomy (group 2), intracoronary abciximab with (group 3) or without
thrombectomy (group 4). Intrastent thrombus at OCT assessment was deﬁned as the
maximum % value of Thrombus area (thrombus area/stent area x 100 in the cross
section with largest thrombus). A value > 16% was considered indicative of high
residual intrastent thrombus. By study design the following angiographic indexes of
myocardial reperfusion were evalueted: TIMI value, corrected TIMI Frame Count
(cTFC) and Myocardial Blush Grade (MBG)
Results: Finally the OCT data were available in 119 patients: 64 had a maximum %
value of Thrombus area  16%, whilst the remaining 55 had a residual intrastent
thrombus >16%. No differences were found between the two groups regarding the
microcirculatory indexes at baseline angiogram. After intervention patients with
intrastent thrombus 16% showed a signiﬁcant improvement in the ﬁnal TIMI value
(2.870.33 vs 2.670.54; p¼0.014) and ﬁnal cTFC (11.714.58vs 17.4417.44; p¼
0.012). No statistically signiﬁcant differences were found for MBG (2.580.59 vs
2.430.76; p¼ 0.254.
Conclusions: Data obtained from the COCATIL II study suggest that the presence of
high residual intrastent thrombus in patients undergoing primary angioplasty is
associated with worsened ﬁnal microcirculatory indexes .
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Background: The utility of manual thrombectomy in patients with ST-elevation
myocardial infarction (STEMI) has been questioned after the recent publication of
the TASTE study (N¼7244). This study was larger than all combined previous
trials published to date and it found no beneﬁt with manual thrombectomy for the
primary outcome of all cause mortality. With these new ﬁndings, we sought to
perform an updated meta-analysis of randomized clinical trials with a focus on clinical
outcomes.
Methods: Medline, Embase and Cochrane detabase as well as conference proceeding
from major cardiology meetings were searched for randomized trials comparing
manual aspiration thrombectomy in addition to percutaneous coronary intervention
(PCI) versus PCI alone in patients presenting with STEMI.
Results: A total of 19 randomized controlled trials enrolled 11,197 patients
presenting with STEMI to either manual thrombectomy and PCI or conventional
PCI. There was a non signiﬁcant trend toward reduction in all cause death with
manual thrombectomy vs. PCI alone (2.9% vs. 3.5% with an odds ratio (OR) of 0.82
(95% CI: 0.66 to 1.01; p¼0.06)). Manual thrombectomy was associated with a
reduction in the incidence of re-infarction (OR: 0.61; 95% CI: 0.42 to 0.88; p¼0.008),
stent thrombosis (OR: 0.54; 95% CI: 0.32 to 0.93; p¼0.02), target lesion revascu-
larization (OR: 0.67; 95% CI: 0.5 to 0.91; p¼ 0.01) and rehospitalisation for
heart failure (OR: 0.25; 95% CI: 0.09 to 0.71; p¼ 0.009). Manual thrombectomy was
not associated with an increase in the risk of stroke (OR: 1.08; 95% CI: 0.62 to 1.87;
p¼ 0.8)).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ThConclusions: Manual thrombectomy reduced the incidence of myocardial re-infarc-
tion, stent thrombosis, target lesion revascularization and rehospitalisation for heart
failure. Further large scale trials are needed to determine the effect of thrombectomy
on mortality.
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Background: The purpose of this observational study was to evaluate the impact of
thrombectomy on in-stent restenosis and stent thrombosis in patients undergoing
primary PCI due to ST-elevation myocardial infarction (STEMI).
Methods: Data were obtained from the SCAAR registry (Swedish Coronary Angi-
ography and Angioplasty Registry) for PCI procedures performed in the county of
Västra Götaland in Sweden between January 2005 and May 2013. The primary
combined endpoint was in-stent restenosis and stent thrombosis. The study population
consisted of 9058 stents that were used in 6595 procedures on 5388 patients. The two
groups were compared using propensity score adjusted multilevel Cox proportional-
hazards regression to account for hierarchical database. Stents were the primary
observation unit, while patients and hospitals were two additional hierarchical clusters.
Adjustments for differences in baseline characteristics were made with propensity
score. The following variables were included in the calculation of the propensity
score: age, gender, indication for PCI, smoking habits, hypertension, diabetes,
hyperlipidaemia, severity of coronary artery disease, previous infarction, previous
PCI, previous coronary artery by-pass surgery (CABG), anticoagulation therapy with
glycoprotein IIb/IIIa receptor antagonists (GP IIb/IIIa), bivalirudin, clopidogrel,
ticagrelor, prasugrel, unfractionated heparin/low-molecular weight heparins (UH/
LMWH), year, hospital, completeness of revascularization, stent length, stent
diameter.
Results: The two groups were balanced regarding age, gender, diabetes, smoking
habits, hypertension, hyperlipidaemia, previous PCI, previous CABG. Patients who
were treated with thrombectomy were more likely to be completely revascularized,
pre-treated with aspirin and clopidogrel, and to receive bivalirudin and drug-eluting
stents during the procedure. Mean follow-up time was 3.3 years. After adjustment, the
use of thrombectomy was not associated with lower risk for stent thrombosis and
restenosis (HR 1.14; 95% CI 0.81–1.63; P ¼ 0.45).
Conclusions: In patients with STEMI, treatment with thrombectomy was not asso-
ciated with decreased risk for in-stent restenosis and stent thrombosis.
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Background: The clinical outcome of intracoronary thrombus aspiration before pri-
mary percutaneous coronary intervention (PCI) in patients with ST-segment elevation
myocardial infarction (STEMI) is controversial. Effective thrombectomy treatment on
myocardial damage has not been evaluated comprehensively. The main goal of this
study is to examine clinical impact of effective thrombectomy (ET) and non-effective
thrombectomy (non-ET)
Methods: We prospectively included 395 patients with TIMI 0 or I ﬂow anterior
STEMI, who underwent p-PCI with thrombus aspiration within 12 hours from
symptom onset. Manual thrombus aspiration devices (6f VMAX Asp. Catheter,
ASTRON, Germany,crossing proﬁle,0.068 in) were used for thrombectomy. Effective
thrombectomy (ET) was deﬁned as achieved visible aspiration material.Non-ET was
deﬁned as no visible aspiration material. No-reﬂow was deﬁned as TIMI grade 0, 1
and 2 ﬂows or TIMI grade 3 with myocardial blush grade 0 and 1. The primary end
points were the occurrence of no-reﬂow and the rate of 90-min ST-segment resolution
>70%. Patients were divided into two groups (ETandnonETgroups) according to their
aspiration materials
Results: Effective thrombectomy was observed 178 (60.3%) of patients. No-
reﬂow was lower in ET group compared with non-ET group 28 (15.7%) and
47 (40.2%), p< 0,001). Baseline clinical and demographic characteristics of the
study were similar. Ejection fraction (EF) and ST-segment resolution were higher,
and hospital mortality, Killip class II-IV and Post-pPCI TIMI frame count were
lower in ET group compared with non-ET group (p< 0.05 for all). Infarction
time, total stent length (mm), initial SYNTAX score, post-primary PCI SYNTAX
score and use of IIb/IIIa glycoprotein inhibitors were similar in two groups (p>0.05
for all).rombectomy B41
